Y mAbs Therapeutics

Y mAbs Therapeutics — Q4 2024 Earnings Presentation

21 slides from Y mAbs Therapeutics's earnings presentation, Mar 4, 2025

  1. Slide 1: Q4 & FY 2024 Financial Results and Corporate Update

    Q4 & FY 2024 Financial Results and Corporate Update March 4, 2025

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre

  3. Slide 3: Mike Rossi: Q4 and FY 2024 Business Highlights

    Mike Rossi President and Chief Executive Officer Q4 and FY 2024 Business Highlights 3

  4. Slide 4: Agenda

    Agenda Q4 & FY 2024 Business Highlights 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Performance 2 Doug Gentilcore, DANYELZA Business Unit Head SADA PRIT Update 3 Natalie Tucker, Radiopharmaceutical Business Unit Head Q4 & FY 2024 Financials, Q1 & FY 2025 Guidance 4 Peter Pfre

  5. Slide 5: Q4 & FY 2024 and Recent Corporate Highlights

    Q4 & FY 2024 and Recent Corporate Highlights ✓ FY 2024 Total Revenues of $87.7M, in-line with January preannouncement and within FY 2024 guidance range of between $87M-$95M ✓ DANYELZA anti-GD2 U.S. market share stable at 15%-17% ✓ Ex-U.S. demand continued to grow through partners and NPPs* ✓ Proof-o

  6. Slide 6: Realignment into Business Units Intended to Accelerate Development in Radiopharmaceuticals

    Realignment into 2 Business Units Intended to Accelerate Development in Radiopharmaceuticals and Maximize Value of DANYELZA Adding dedicated internal resources, increasing flexibility, and optimizing Expand Radiopharmaceutical Capabilities operations is critical to advancing our Radiopharmaceutical

  7. Slide 7: Doug Gentilcore: DANYELZA Global Performance

    Doug Gentilcore DANYELZA Business Unit Head DANYELZA Global Performance 7

  8. Slide 8: DANYELZA Global Commercial Update

    Q4 & FY 2024 DANYELZA Global Commercial Update • Q4 2024 Total DANYELZA Net Product Revenues of $24.5M,  5% YoY • Q4 2024 ex-U.S. DANYELZA Net Product Revenues of $7.7M,  78% YoY • 69 U.S. accounts* since initial launch; 11 new accounts added in FY 2024 • DANYELZA remains a leading therapy in U.S.

  9. Slide 9: Natalie Tucker: SADA PRIT Update

    Natalie Tucker Radiopharmaceutical Business Unit Head SADA PRIT Update 9

  10. Slide 10: GD2-SADA Phase 1 Clinical Trial (Trial 1001): Part A Closed

    GD2-SADA Phase 1 Clinical Trial (Trial 1001): Part A Closed Pretargeted theranostic platform for treatment of GD2 positive solid tumors Trial Overview Part A Determine optimal, well- tolerated GD2-SADA protein Part A Data Anticipated to be • Solid tumors: SCLC, dose and dosing interval Presented in

  11. Slide 11: CD38-SADA Phase 1 Clinical Trial (Trial 1201): Trial Design

    CD38-SADA Phase 1 Clinical Trial (Trial 1201): Trial Design Pretargeted theranostic platform for treatment of CD38 positive hematological tumors Inclusion Criteria Part A Part B N = 12 – 15 N = 12 – 15 • R/R non-Hodgkin TRIAL UPDATE Lymphoma and ineligible/ exhausted standard DESIGN CD38-SADA protei

  12. Slide 12: Anticipated GD2-SADA Q2 2025 Data Readout

    Anticipated GD2-SADA Q2 2025 Data Readout Q2 2025 Planned Trial: Ongoing Trial 1001 (GD2-SADA) Platform Optimization Bridge to 1001 Part B Phase 1: Optimization Workstreams Evaluate Optimized GD2-SADA Part A Data Readout Underway Platform • Optimize chelator • Current 1001 IND with protocol ✓ Safety

  13. Slide 13: Y-mAbs' Comprehensive Radiopharmaceutical Target Identification Process

    Y-mAbs’ Comprehensive Radiopharmaceutical Target Identification Process Next Cohort of Potential High-Value Oncology Targets for Development with SADA PRIT Selection to determine suitability Prioritized target archetypes for Targets diversified across tumor types, but also for targeting with SADA PR

  14. Slide 14: Peter Pfreundschuh: Financials and Q1 & FY 2025 Guidance

    Peter Pfreundschuh Chief Financial Officer Q4 & FY 2024 Financials and Q1 & FY 2025 Guidance 14

  15. Slide 15: Key Financial Highlights: Revenue

    Key Q4 & FY 2024 Financial Highlights Revenue Three months ended Dec 31, 12 months ended Dec 31, 2024 2023 2024 2023 Net product revenue $24.5 M $23.4 M Net product revenue $85.2 M $84.3 M License revenue $2.0 M – License revenue $2.5 M $0.5 M Total revenue $26.5 M $23.4 M Total revenue $87.7 M $84.

  16. Slide 16: Key Financial Highlights: Operating Expenses

    Key Q4 & FY 2024 Financial Highlights Operating Expenses Three months ended Dec 31, 12 months ended Dec 31, 2024 2023 2024 2023 License royalties $0.2 M – License royalties $0.25 M $0.05 M Research & development $12.2 M $13.4 M Research & development $49.0 M $54.2 M Selling, general & admin $12.4 M

  17. Slide 17: Key Financial Highlights: Net Loss

    Key Q4 & FY 2024 Financial Highlights Net Loss Three months ended Dec 31, 12 months ended Dec 31, 2024 2023 2024 2023 Net loss $(6.8) M $(1.0) M Net loss $(29.7) M $(21.4) M Net loss per basic, diluted share $(0.15) $(0.02) Net loss per basic, diluted share $(0.67) $(0.49) 17

  18. Slide 18: Key Financial Highlights: Responsible stewards of capital

    Key Q4 & FY 2024 Financial Highlights Responsible stewards of capital As of 12 months ended Dec 31, Dec 31, 2024 Dec 31, 2023 2024 2023 Cash and cash equivalents $67.2 M $78.6 M Cash use $11.4 M $27.1 M Anticipated cash runway Total Annual Cash into 2027* Investment  58% YoY *This estimate reflects

  19. Slide 19: Financial Guidance for Q1 and Full Year 2025

    Financial Guidance for Q1 and Full Year 2025 FY 2024 Total Expected Revenues: $75 million to $90 million Q1 2024 Total Expected Revenues: $18 million to $21 million Total Expected Operating Costs and Expenses: $116 million to $121 million Total Expected Annual Cash Investment: $25 million to $30 mil

  20. Slide 20: Q&A

    Q&A Mike Rossi Doug Gentilcore President and DANYELZA Business Chief Executive Officer Unit Head Natalie Tucker Peter Pfreundschuh Radiopharmaceutical Chief Financial Officer Business Unit Head 20

  21. Slide 21: Thank You

    Thank You

Y-mAbs Therapeutics — Q4 2024 Earnings Presentation on 6ix